HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Tamoxifen and its active metabolite inhibit growth of estrogen receptor-negative MDA-MB-435 cells.

AbstractTamoxifen (TAM), the non-steroidal anti-estrogen most widely administered to breast cancer patients, acts, at least in part, by competing with estrogen receptors (ER). However, the existence of an alternative mechanism of action for this drug is supported by the clinical observations that: (a) 30% of patients with ER-negative cancer cells respond to TAM, and (b) 30% of patients with ER-positive cancer cells are not sensitive to this anti-estrogen. In this study, we observed that growth of the human ER-negative breast cancer cell line MDA-MB-435 was inhibited by TAM and 4-hydroxytamoxifen (4OH-TAM) in a concentration-dependent fashion. Both monoclonal enzymoimmunoassay and Dextran Charcoal Coated Scatchard radioimmunoassay analysis demonstrated that this MDA-MB-435 cell line does not express ER. The absence of ER in MDA-MB-435 cells was also demonstrated at the mRNA level by both northern blot hybridization and reverse transcription-polymerase chain reaction techniques. MDA-MB-435 cell proliferation was not affected by 17 beta-estradiol or by the pure anti-estrogen ICI 164384, further demonstrating that the observed effects of TAM and its active metabolite on the proliferation of MDA-MB-435 cells were due to an ER-independent mechanism, yet to be identified. MDA-MB-435 thus appears to be a promising original model for the study of the alternative ER-independent mechanisms of action of TAM.
AuthorsC Charlier, A Chariot, N Antoine, M P Merville, J Gielen, V Castronovo (Affiliation: Metastasis Research Laboratory, University of Liège, Belgium.)
JournalBiochemical pharmacology (Biochem Pharmacol) Vol. 49 Issue 3 Pg. 351-8 (Jan 31 1995) ISSN: 0006-2952 [Print] ENGLAND
PMID7857322 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Estrogens
  • RNA, Messenger
  • Receptors, Estrogen
  • Tamoxifen
  • 4-hydroxytamoxifen
Topics
  • Breast Neoplasms (prevention & control)
  • Cell Division (drug effects)
  • Estrogens (pharmacology)
  • Humans
  • RNA, Messenger (analysis)
  • Receptors, Estrogen (analysis, genetics)
  • Tamoxifen (analogs & derivatives, pharmacology)
  • Tumor Cells, Cultured (drug effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password:


Research Interface PRO additionally includes drill-down to evidence, articles by author, export to Excel, FDA Link and mobile subscription:
1 year subscription, $45.00 USD